Early Puberty During Pandemic; Wegovy Protects Heart; Weight Loss Drugmakers Sued

More girls started precocious puberty during the COVID-19 pandemic compared with the prior 4 years, with the researchers citing stress, social isolation, increased conflicts between parents, economic status, and the increased use of hand and surface sanitizers as potential hypotheses as to why early puberty is increasing. (Journal of the Endocrine Society)

Artificial intelligence (AI)-augmented automated insulin delivery systems may be able to integrate exercise data from wearable fitness sensors like smartwatches in order to better inform insulin dosing in people with type 1 diabetes. (The Lancet Digital Health)

Semaglutide 2.4 mg (Wegovy) cut the risk of major adverse cardiovascular events by 20% in people with overweight or obesity and a history of cardiovascular disease in the SELECT trial, said maker Novo Nordisk.

Researchers discuss the challenges of Cushing disease management in adults. (Nature Reviews Endocrinology)

A personal injury law firm filed a suit against Novo Nordisk and Eli Lilly, the manufacturers of the GLP-1 receptor agonist semaglutide (Ozempic) and combo GIP/GLP-1 receptor agonist tirzepatide (Mounjaro), over claims that the drugs can cause gastroparesis. (CBS News)

Injectable treatment, lack of insurance coverage, and weight rebound — these were three of the top reasons that people lose interest in taking popular weight loss drugs, according to a KFF poll.

A phone app for basal insulin titration helped to modestly but significantly lower HbA1c levels among patients with type 2 diabetes compared with basal insulin titration guided by a written titration schedule. (The Lancet Regional Health- Europe)

An elementary school program that promoted water over sugary drinks showed some benefit when it came to rates of overweight in kids. (Pediatrics)

Please enable JavaScript to view the

comments powered by Disqus.